Apogee Enterprises Reports Fiscal 2027 First Quarter Results
Apogee Enterprises Reports Fiscal 2027 First Quarter Results
First-quarter net sales of $342.7 million
First-quarter diluted EPS of $0.54 and adjusted diluted EPS of $0.57
Pending Kalwall acquisition on track for early July close, advancing strategy to expand into higher-growth differentiated product offerings
Company reaffirms fiscal 2027 guidance
Why Is Apogee Enterprises Stock Soaring Friday? - Apogee Enterprises (NASDAQ:APOG)
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Mov
Apogee Enterprises, Synaptics And 3 Stocks To Watch - Apogee Enterprises (NASDAQ:APOG)
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic
Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On Monda
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition - AbbVie (NYSE:ABBV), Apogee Ther
AbbVie to buy Apogee Therapeutics in nearly $11B deal
AbbVie compra la 'biotech' Apogee por 10.900 millones de d�lares
AbbVie compra Apogee per 10,9 mld $ | MilanoFinanza News
Apogee Enterprises Announces Date for Fiscal 2027 First Quarter Results
Apogee (APOG) stock surges after Q1 2027 earnings and revenue beat Wall Street estimates. Read the full financial breakdown here.
Apogee Enterprises Inc (NASDAQ: APOG) rose sharply after the company reported better-than-expected first-quarter financial…
APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its…
U.S. stock futures are down, but some stocks to watch today include Apogee, BitGo, Cineverse, Synaptics and Beyond Air.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apogee Therapeutics, Inc. (NASDAQ: APGE)
